| S |
|
Safe anti-coagulation with danaparoid in pregnancy and lactation
|
| Schindewolf M., Mosch G., Bauersachs R. M., Lindhoff-Last E. |
| |
|
Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency
|
| Dreyfus M., Arnuti B., Beurrier P., Borg J. Y., Clayssens S., Girardel J. M., Pouzol P., Seaume H., Torchet M. F., Pautard B., Pernod G., Muysers C., Barrois D. |
| |
|
Safety and efficacy of nadroparin for the treatment or prophylaxis of venous thromboembolism in pregnancy
|
| Barillari G., Springolo F., Santuz M., Biffoni F. |
| |
|
Safety and efficacy of using Low-Molecular-Weight Heparins to bridge patients on long-term warfarin
|
| Jaffer A., Ahmed M., Bragg L., Seshadri N., Klein A. |
| |
|
Safety and Pharmacoeconomic Aspects
|
| Bohn R. |
| |
|
Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study
|
| Murray P., Reddy B., Grossman E., Hammes M., Trevino S., Ferrell J., Tang I., Khorana A., Fosbinder T., Swan S. K. |
| |
|
Safety considerations of Enoxaparin as an alternative to oral anti-coagulants in high risk cardioembolic patients with a programed surgical procedure. SWITCH trial
|
| Ceresetto J., Casei M., Xavier L., Anselmo A., Fitz Maurice M., Duboscq C., Shanley C., Stemmelin G., Rabinovich O., Bullorsky E. |
| |
|
Safety of low intensity warfarin regimen in Chinese patients With mechanical heart valve prostheses
|
| El Rouby S., Chan L., Laduca F. M., Zucker M. L., CHINESE CO-OP ANTICOAGULATION‡ |
| |
|
Safety of the transfer of patients on anticoagulant therapy from hospital anticoagulant clinics to general practitioners using a computer-decision support
|
| Mavri A., Stigl B., Merviè J., Tratar G., Stalc M., Vizintin T., Terbizan M., Vene N., Peternel P. |
| |
|
Safety, efficiency and dose saving of continuous infusion modality of protein C concentrate in the management of a protein deficient patient submitted to orthopedic surgical procedure
|
| Barillari G., Giacomello R., Monesi M., Biffoni F. |
| |
|
Sample management and quality control in roTEG thrombelastography
|
| Christiansen K., Sorensen B., Ingerslev J. |
| |
|
Screening for annexin A5 gene mutations and the risk of the C-1T mutation in venous thrombosis and myocardial infarction
|
| Kenis H., Doggen C. J. M., Rosendaal F. R., Bertina R. M., Vos H. L., Hamulyak K., Jumilly A.-L., Lavergne J.-M. L. S., Reutelingsperger C. P. M., Van Heerde W. L. |
| |
|
Screening for asymptomatic deep vein thrombosis after major orthopedic surgery: findings of the Global Orthopaedic Registry (GLORY)
|
| Agnelli G., Gallus A ., Kuznetsova P., Glory Investigators |
| |
|
Screening for the Factor V Leiden mutation with a Russell's viper venom-based clotting test
|
| Kershaw G., Yeun E., Rickard K. |
| |
|
Screening for thrombophilia: an economic assessment
|
| Wu O., Robertson L., Twaddle S., Clark P., Lowe G., Walker I., Brenkel I., Greaves M., Langhorne P., Regan L., Greer I. |
| |
|
Screening of high factor VIII levels is not recommended in patients with recently diagnosed pulmonary embolism
|
| Kamphuisen P. W., Ten Wolde M., Jacobs E. M. G., Ullmann E. F., Koopman M. M. W., Buller H. R. |
| |
|
Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period
|
| Deitcher S. R., Kessler C. M., Merli G., Rigas J., Lyons R. M., Cort S. |
| |
|
Secondary stereoselectivity of enzymes with a strictly specific action
|
| Poyarkova S. |
| |
|
Secondary thromboprophylaxis program assessing the efficacy of mini dose warfarin and prothrombin fragment 1 + 2 in selected high risk patients with venous thromboembolism
|
| Tran H., Wheeler M. L., Gan T. E. |
| |
|
Selection and characterization of a novel factor XI inhibiting peptide by using phage display technology
|
| Meiring M., Motloi N. C., Gruber A. |
| |
|
Self-management of oral anti-coagulation reduces the incidence of complications: preliminary results of the ACOA clinical trial
|
| Jándula B. M., Montserrat I., Souto J. C., Gich I., Fontcuberta J. |
| |
|
Senescent rabbit platelets, or rabbit platelets with experimentally shortened survival, are apoptotic with increased surface exposure of procoagulant phosphatidylserine (PS)
|
| Rand M., Wang H., Bang K. W. A., Poon K. S. V., Packham M. A., Freedman J. |
| |
|
Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD)
|
| Castaman G., Tosetto A., Rodeghiero F., Peake I. R., Goodeve A., Federici A. B., Battle J., Meyer D., Eikenboom J. C. M., Schneppenheim R., Ingerslev J., Vorlova Z., Lethagen S., Pasi J., Hill F. |
| |
|
Sensitivity and specificity of the abnormal optical waveform profile in the prothrombin time from patients with antiphospholipid antibodies
|
| Su Z., Pound M. L., Baker K. R., Thames E. H., Ortel T. L. |
| |
|
Sensitivity of platelet retention test Homburg (RTH) in drug monitoring and measuring vs. Willebrand factor–mediated platelet adhesiveness
|
| Wieding J. U., Werms C., Peine S., Köstering H., Wenzel E. |
| |
|
Sensitivity of semiquantitative lupus anticoagulant test for the diagnosis of antiphospholipid syndrome
|
| Atsumi T., Ieko M., Jodo S., Amasaki Y., Koike T. |
| |
|
Sequential adhesion of platelets and then leukocytes from blood flowing over collagen in simple laminar and disturbed flow
|
| Nash G., Butler L. M., Metson-Scott T., Skilbecck C. |
| |
|
Serial changes in hemostasis following subarachnoid hemorrhage
|
| Albon H. K., Mcevoy A. W., Mackie I., Kitchen N. D. |
| |
|
Serine proteases–mediated serotonin release and its inhibition by argatroban and other direct thrombin inhibitors: Implications in the control of thrombogenesis
|
| Ahmad S., Fenton J. W., Osakabe M., Iqbal O., Hoppensteadt D. A., Messmore H. L., Fareed J. |
| |
|
Serum homocysteine in chronic liver diseases – risk factor for thrombosis or protection against thrombosis?
|
| Remkova A., Kovacova E., Boca M., Kratochvilova H. |
| |
|
Serum levels of the anti-inflammatory cytokine interleukin-10 are inversely associated with future events in patients with previous acute myocardial infarction
|
| Seljeflot I., Hurlen M., Arnesen H. |
| |
|
Seven novel mutations leading to congenital coagulation factor XIII deficiency
|
| Schroeder V., Cung T., Meili E., Kohler H. P. |
| |
|
Severe factor VII deficiency caused by a new point mutation combined with a previously undetected gene deletion
|
| Hewitt J., Ballard J., Nelson T., Smith V. C., Pritchard S., Wu J. K., Wadsworth L. D., Casey B., Macgillivray R. T. A. |
| |
|
Severe intracranial hemorrhage in a patient with von Willebrand disease type 2B after being hit by a golf ball
|
| Mosler K., Christaras A., Bernbeck B. |
| |
|
Severe thrombophilia in two brothers due to novel combination of mutations in factor V gene producing quantitative deficiency (Glu119Term) and decreased sensitivity to activated protein C due to a novel glycosylation site (Ile359Thr-FV Liverpool)
|
| Bolton-Maggs P., Mumford A., Mcvey J., Tuddenham E. G. D., Steen M., Norstrom E., Dahlback B. |
| |
|
Shear rate of plasma flow and fibrin specificity of thrombolytic agent promote thrombolysis of nonretracted and retracted whole blood clots – a MRI study in vitro
|
| Tratar G., Blinc A., Strukelj M., Mikac U., Sersa I. |
| |
|
Shear stress and the high molecular weight vWF multimers in thrombus formation
|
| Lopez J. |
| |
|
Shear-induced activation of metastatic cells is enhanced by the platelet secreteome and inhibited by aspirin
|
| Lawler K., Meade G., O'Sullivan G., Kenny D. |
| |
|
Shedding of active tissue factor (TF) by rat aortic smooth muscle cells (SMCs) undergoing apoptosis
|
| Brisset A. C., Essayagh S., Dupouy D., Terrisse A. D., Boneu B., Sie P. |
| |
|
Shiga toxin interactions with platelets: differential effects of anti-coagulants and platelet isolation procedures
|
| Ghosh S. A., Polanowska-Grabowska R., Fujii J., Obrig T. G., Gear A. R. L. |
| |
|
Shiga toxin with antecedent TNF-a induces enhanced tissue factor activity on human glomerular, but not on umbilical vein, endothelial cells
|
| Nestoridi E., Kushak R. I., Schumann S. A., Ingelfinger J. R., Grabowski E. F. |
| |
|
Short-term effects of raloxifene on the main anti-coagulant systems in postmenopausal women
|
| Marino R., Cicinelli E., Scaraggi F. A., Galantino P., Lapecorella M., De Mitrio V. |
| |
|
Should prophylaxis be continued after discharge in surgical patients?
|
| Hull R. |
| |
|
Sialic acid and lipid contents of low density lipoprotein in relation to platelet receptor activity
|
| Hartwich J., Skrzeczynska J., Bzowska M., Kwaceniak M., Rostworowski W., Motyka M., Pryjma J., Dembinska-Kiec A. |
| |
|
Sibling stem cell transplant to cure Bernard Soulier Syndrome
|
| Bolton-Maggs P. H. B., Keenan R., Caswell M. |
| |
|
Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes
|
| Shet A.S., Aras O., Gupta K., Hass M.J., Rausch D.J., Koopmeiners L., Saba N., Key N.S., Hebbel R.P. |
| |
|
Sickle cell disease, vascular endothelium dysfunction, abnormal endothelin-1 release, interleukin-6 plasma level, hyperhomocysteinaemia and thromboembolic risk
|
| Musso R., Cultrera D., Chiarenza A., Figuera A., Sortino G., Guarnaccia G., Azzaro M. P., Di Francesco E., Giustolisi R. |
| |
|
Signaling events underlying thrombus formation
|
| Jackson S., Nesbitt W. S., Kulkarni S. |
| |
|
Signaling through GPIb with reference to PI 3-kinase and Src
|
| Ozaki Y. |
| |
|
Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe haemophilia A in the Czech Republic
|
| Habart D., Hrachovinova I., Kalabova D., Vorlova Z. |
| |
|
Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity
|
| Lipari M., Yang J., Moran P., Peek M., Eigenbrot C., Kelley R. F., Kirchhofer D. |
| |
|
Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors in hyperththyroisis
|
| Shuyan Z., Duanwei Z., Zhauchao Y. |
| |
|
Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies
|
| Owaidah T., Zahrani H., Qurashi F., Nounou M., Mussa A., Tbakhi A., Daama S., Elkum N., Roberts G. |
| |
|
Single-dose use of recombinant factor VIIa (NovoSeven) for correction of hepatic-induced coagulopathies prior to minor, invasive procedures
|
| Lyengar S., Duncan A., Martinez E., Nolen J. D. L. |
| |
|
Sinus venous thrombosis in children – a multifactorial etiology
|
| Nowak-Goettl U., Heller C. H., Junker R., Knoefler R., Kosch A., Kurnik K., Schobess R., Von Eckardstein A., Zieger B., Straeter R. |
| |
|
Smoking and abnormalities of coagulation-fibrinolysis in patients with coronary heart disease
|
| Koziri A., Avramakis G., Sfiridaki K., Zaharaki A., Georgas G., Defilippis L., Tsoutsoumanou K., Manousakis E., Skandalakis G., Ploumidis L. |
| |
|
Smooth muscle cell recolonization of the aneurysmal thrombus is prevented by storage of leukocyte elastase in fibrin matrix
|
| Touat Z., M'Tairag E., Jacob M., Meilhac O., Michel J., Fontaine V. |
| |
|
Snake venoms as probes of mechanisms
|
| Andrews R. |
| |
|
Solubilization of CD40L (CD154) from platelets after activation and secretion: proteolysis directly on the platelet surface or after receptor-mediated internalization?
|
| Otterdal K., Pedersen T.M., Solum N. O. |
| |
|
Soluble CD-146 and other markers of endothelial function are elevated in peritoneally dialyzed and chronic renal failure patients
|
| Malyszko J., Malyszko J. S., Mysliwiec M. |
| |
|
Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration
|
| Bardin N., Anfosso F., Daniel L., Moal V., Brunet P., Sampol J., Dignat George F. |
| |
|
Soluble CD40 ligand (sCD40L) plasma levels in nonsmall cell lung cancer
|
| Roselli M., Mineo T. C., Basili S., Martini F., Mariotti S., Aloe S., Bellotti A., Ambrogi V., Spila A., D'Alessandro R., Davì G., Guadagni F., Ferroni P. |
| |
|
Soluble endothelial cell markers (sTM, sEPCR and sVWF) in type 2 diabetes
|
| Ireland H., Konstantoulas C., Humphries S. E., Braitch M., Goodall A. H., Toh C. H., Kurosawa S., Stearns-Kurosawa D. J., Mather H. |
| |
|
Soluble platelet GPV: a new marker of thrombosis status
|
| Shao B., Liu C., Yang X., Lv M., Bai X., Zhai W., Cheng X., Tang H., Yang X., Shi B., Ruan C. |
| |
|
Soluble P-selectin and P-selectin expression (CD62P) both reflect the same in vivo platelet activation
|
| Kennedy G., Mclaren M., Belch J. J. F. |
| |
|
Soluble tissue factor released by cultured human umbilical vein endothelial cells is microparticle-associated and triggers thrombus formation in vivo
|
| Abid Hussein M., Biró É., Meesters E. W., Osmanovic N., Romijn F. P. H. TH. M., Vogel G. M. T., Meuleman D. G., Sturk A., Nieuwland R. |
| |
|
Some aspects of human immunity against heat shock proteins 60/65
|
| Wick G., Bobrovnik S. A. |
| |
|
Species dependence on nitric oxide generation: pharmacological implications on animal modeling
|
| Fareed D., Neville B., Iqbal O., Hoppensteadt D. |
| |
|
Specific and nonspecific antiphospholipid antibodies in recurrent fetal loss: a meta-analysis
|
| Opatrny L., David M., Kahn S. R., Shrier I., Rey E. |
| |
|
Specific interaction of the proteolytic SPII fragment of von Willebrand factor with fibrin
|
| Keuren J., Baruch D., Legendre P., Girma J.-P., Lindhout T. |
| |
|
Specific phosphatidylserine exposure and microparticules shedding induced by a synthetic peptide
|
| Adam F., Huisse M. G., Verbeuren T. J., Fauchere J. L., Guillin M. C., Jandrot-Perrus M. |
| |
|
Specificity and redundancy of G-protein pathways in agonist-induced alpha granule release in human platelets
|
| Murugappan S., Quinton T. M., Kunapuli S. P. |
| |
|
Specificity of coagulation factor signaling
|
| Ruf W., Dorfleutner A., Riewald M. |
| |
|
Sphingosine 1-phosphate-related metabolism in the blood
|
| Shinya A., Yatomi Y., Ohta M., Osada M., Ozaki Y. |
| |
|
Sphingosine and certain sphingolipid analogs are potent anticoagulants as prothrombinase inhibitors
|
| Deguchi H., Griffin J. H. |
| |
|
Spinal cord vascular malformations: imaging and endovascular treatment
|
| Liu Y., Li A. |
| |
|
Spiral computed tomography has a higher sensitivity and specificity than d-dimer in the diagnosis of acute pulmonary embolism
|
| Nilsson T., Söderberg M., Lundqvist G., Cederlund K., Larsen F., Rasmussen E., Svane B., Brohult J., Johnsson H. |
| |
|
Splenectomy in relapsing and plasma-refractory thrombotic thrombocytopenic purpura
|
| Kremer Hovinga J., Studt J. D., Alberio L., Demarmels Biasiutti F., Solenthaler M., Fontana S., Mansouri Taleghani B., Lämmle B. |
| |
|
Splice site mutations of the von Willebrand factor gene in patients previously diagnosed with von Willebrand disease type 1
|
| Schneppenheim R., Baronciani L., Budde U., Goodeve A., Hill F., Lambert J., Obser T., Oyen F. |
| |
|
SPR evaluation of antibody-mediated inhibition of recombinant FVIII (full length and B-domain deleted) binding to von Willebrand factor
|
| Mccormick A. N., Savidge G., Saint-Remy J. M., Alhaq A. |
| |
|
SRC-dependent signaling is a key step in the process of autoregulation of Mac-1 adhesive function in human PMN
|
| Piccardoni P., Bagoly S., Manarini S., Piccoli A., Pecce R., Cerletti C., Totani L., Evangelista V. |
| |
|
SSC classification of hemophilia A: is it achievable? A UKNEQAS supplementary exercise
|
| Preston F. E., Jennings I., Kitchen S., Woods T. A. L., Makris M. |
| |
|
Stability of 19 mutated recombinant von Willebrand factor to von Willebrand factor-cleaving protease (ADAMTS13)
|
| Tout H., Houllier A., Obert B., Ribba A. S., Hilbert L., Mazurier C., Meyer D., Girma J. P. |
| |
|
Stability of dilutions of the recombinant factor VIII Kogenate FS stored in syringes
|
| Rand M., Schmugge M., Clark D., Lillicrap D., Blanchette V. S. |
| |
|
Stability of rFVIII-FS after continuous infusion using a mini-pump infusion device
|
| Henze W., Kellermann E., Gorina E., Larson P. |
| |
|
Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed with commercial and home made methods
|
| Chantarangkul V., Tripodi A., Valsecchi C., Battaglioli T., Mannucci P. M. |
| |
|
Standardization of circulating endothelial cell enumeration in whole blood
|
| Combier C., Terstappen L. W. M. M., Rao C., Canton M., Moulard M. |
| |
|
Statin regulation of extrinsic thrombin generation
|
| Fenton II J. W., Moon D. G., Jeske W. P., Catalfamo J. L., Shen G. X., Ofosu F. A. |
| |
|
Statins inhibit cyclo-oxygenase (cox)-2 and metalloproteinase (mmp)-9 expression in human endothelial cells: possible contribution to plaque stability
|
| Massaro M., Zampolli A., Carluccio M. A., Distante A., Storelli C., De Caterina R. |
| |
|
Stem cell mobilization and differentiation to endothelial cells
|
| Dimmeler S. |
| |
|
Stem cell vascular regeneration
|
| Asahara T. |
| |
|
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y12 receptor antagonist
|
| Jakubowski J., Ogawa T., Sugidachi A., Hasegawa M., Tsutsumi S., Yoneda K., Iwamura R., Kimura T., Asai F. |
| |
|
Sticky platelet syndrome
|
| Makris P. E., Girtovitis F., Anestakis D., Pithara E. |
| |
|
Stimulation by antithrombin of sensory nerve-mediated anti-inflammatory pathway in rats
|
| Harada N., Okajima K., Uchiba M. |
| |
|
Stimulation of PAR-1 does not lead to G protein redistribution in human platelets
|
| Kahner B., Quinton T. M., Kunapuli S. P. |
| |
|
Storage of apheresis platelets leads to reduced adhesiveness and thrombogenic activity in flowing whole blood ex vivo
|
| Curvers J., Van Pampus E. C. M., Feijge M. A. H., Rombout E., Heemskerk J. W. M. |
| |
|
Stored platelets contain residual amounts of tissue factor
|
| Pérez-Pujol S., Lozano M., Aras O., Key N., White J. G., Mc Cullough J., Escolar G. |
| |
|
Stroke: killer clots and killer drugs
|
| Warlow C. |
| |
|
Structural and functional characterization of a new transcription factor (6A3-5) potentially implicated in changes of smooth muscle cells phenotype
|
| Garin G., Zibara K., Hurlstone A., McGregor J.L. |
| |
|
Structural aspects of fibrinogen to fibrin transition
|
| Medved L. |
| |
|
Structural basis for differences in heparin-dependence of endothelial cell proliferative activities of human FGF-1 and FGF-2
|
| Peng H., Sahni A., Francis C. W. |
| |
|
Structural elements in tissue-type plasminogen activator contributing to its storage in primary endothelial cells
|
| Fish R., Yang H., Kruithof E. K. O. |
| |
|
Structure function of tissue factor pathway inhibitor
|
| Mast A. |
| |
|
Structure of fibrinogen
|
| Doolittle R. F. |
| |
|
Structure of the alphaVbeta 3 receptor
|
| Xiong J-P., Stehle T., Goodman S. L., Arnaout M. A. |
| |
|
Structure of the Glycoprotein Ib N-terminal domain
|
| Emsley J., Clemetson J., Clemetson K., Harrison T., Uff S. |
| |
|
Structure of the platelet glycoprotein Iba N-terminal domain
|
| Emsley J. |
| |
|
Studies of anti-idiotypic polyclonal antibodies developed against antihuman Factor VIII monoclonal antibodies
|
| Raut S., Villard S., Granier C., Gilles J.G.G., Saint-Remy J.M.R., Baroowcliffe T.W. |
| |
|
Studies of blood coagulation and platelet function in thoracic surgery utilizing a point of care instrument, a free oscillation rheometer
|
| Gustafsson K., Rånby M., Feder J., Cederholm I., Berg S., Lindahl T. L. |
| |
|
Studies of the relationship between elevated factor VIII level and ischemic stroke in China
|
| Yang P., Xue J., Li X. |
| |
|
Studies to define the clinical impact of ‘mild’ hemophilia A in a large kindred in Newfoundland and Labrador
|
| Scully M. F., Barrett B., Hann A. H., Macgregor D., Walsh M., Xie Y. |
| |
|
Subcutaneous adjusted-dose unfractionated heparin vs. fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism
|
| Prandoni P., Carnovali M., Marchiori A., Ghirarduzzi A., Girolami B., Quintavalla R., Tropeano P. F., Alatri A., Accorsi F., Todini A. R., Moia M., Scannapieco G. L., Villalta S., Cogo A., Imberti D., Parente F., Agnelli G., Sartori D., Cuppini S., Migliacci R., Corà F., Bagatella P., Girolami A. |
| |
|
Subcutaneous administration of protein C
|
| Mathias M., Khair K., Burgess C., Liesner R. |
| |
|
Subpopulations of tissue factor-exposing microparticles from platelets and T-cells colocalize leukocytic antigens in uncomplicated human type 2 diabetes
|
| Diamant M., Nieuwland R., Böing A. N., Snoeck D. P., Smit J. W. A., Radder J. K., Sturk A. |
| |
|
Subsequent diagnosis of malignancy in patients presenting with an idiopathic venous thromboembolism – a number needed to screen and decision analysis based on the results of a prospective study
|
| Otten J. M. M. B., Piccioli A., Richel D. J., Lensing A. W. A., Prandoni P., Büller H. R., Prins M. H. |
| |
|
Substitutes and alternatives to platelet transfusions in thromocytopenic patients
|
| Blajchman M. A. |
| |
|
Substitutions of conserved Gly193 (numbering according to chymotrypsin) located near the catalytic triad of factors VII, IX and XI yield dysfunctional proteins probably due to interference with accessibility of the respective substrates
|
| Zivelin A., Cohen-Landau M., Rosenberg N., Seligsohn U. |
| |
|
Successful antithrombotic therapy employing intravenous bolus low molecular weight heparin in an extremely preterm infant
|
| Manco-Johnson M., Knapp-Clevenger R. |
| |
|
Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II
|
| Kamei M., Miyata S., Niwaya K., Bando K., Tsuji T., Suzuki S., Hanatani A., Ohnishi Y., Uchida O., Kuro M., Imanaka H., Kobayashi J., Yagihara T., Nakatani T. |
| |
|
Successful immune tolerance therapy in hemophilia B patients with fix: a new immunesuppressive strategy
|
| Martinez-Saguer I., Klarmann D., Knöfler R., Escurila-Ettingshausen C., Funk M., Linde R., Aygören-Pürsün E., Stoll H., Klingebiel T., Kreuz W. |
| |
|
Successful liver transplantation in a hemophilia A patient with high titer factor VIII inhibitor
|
| Key N., Ashrani A., Reding M. T., Shet A., Osip J., Humar A., Lake J. R. |
| |
|
Successful outcome of rituximab therapy for spontaneous refractory high titer FVIII inhibitors
|
| Ahn Y., Kett D., Gangliano-Decesare T., Jy W., Tiede M., Horstman L. |
| |
|
Successful treatment with rituximab in a case of relapsed acquired hemophilia
|
| Beneke H., Güthner C., Struve S., Griesshammer M., Grünewald M. |
| |
|
Successful use of Arixtra® in a patient with PNH, Budd–Chiari syndrome and HIT
|
| D'Amico E., Villaça P. R., Gualandro S. F. M., Bassitt R. P., Silveira P. A. A., Rocha T. R. F., Chamone D. A. F. |
| |
|
Successful use of recombinant activated factor VII for controlling bleeding in patients receiving invasive surgeries
|
| Chuansumrit A., Wanitkun S., Teeraratakul S., Attanawanich S., Jirapradittha J., Hongeng S. |
| |
|
Successful use of recombinant FVIIa (Novoseven) for severe bleeding in a patient undergoing bone marrow transplantation refractory to standard hemostatic support
|
| Perez-Montes R., Bermudez A., Arce O., Lopez-Duarte M., Sedano C., Zubizarreta A. |
| |
|
Successful use of rFVII for an hemorrhagic Port-a-cath insertion in a Fanconi's disease
|
| Belkaid I., Ricard C., Henni T. |
| |
|
Suitable Measurement of anti-factor Xa activity
|
| Samama M. |
| |
|
Suppression of thrombin generation and fibrinolysis in patients with rheumatoid arthritis treated with anti-TNFa monoclonal antibody (Infliximab)
|
| Gluszko P., Lowenhoff T., Undas A., Kwasny-Krochin B., Skura A., Iwaniec T. |
| |
|
Surface deposited fibrin activates factor XII and the intrinsic coagulation pathway
|
| Sanchez J., Larsson R., Olsson P. |
| |
|
Surface exposed mutation W2313A in the C2-domain of FVIII results in defective secretion of otherwise functional protein
|
| Schatz S., Zimmermann K., Hasslacher M., Kerschbaumer R., Dockal M., Gritsch H., Turecek P., Dorner F., Scheiflinger F. |
| |
|
Symptomatic chronic thromboembolic pulmonary hypertension after symptomatic pulmonary embolism: incidence and risk factors: a long-term follow-up study
|
| Pengo V., Lensing A. W. A., Prins M. H., Marchiori A., Davidson B. L., Tiozzo F., Albanese P., Biasiolo A., Pegoraro C., Iliceto S., Prandoni P. |
| |
|
Symptomatic plaques of type 2 diabetic patients show more plaque complications but similar expression patterns of markers for coagulation and inflammation compared to nondiabetic controls
|
| Sommeijer D. W., Beganovic A., Schalkwijk A., Van Aken B. E., Ten Cate H., Van Der Wal A. C. |
| |
|
Synergy between deficiencies of plasma glucosylceramide and deficiency of activated protein C for venous thromboembolism
|
| Deguchi H., Espana F., Medina P., Aznar J., Lee Y. M., Griffin J. H. |
| |
|
Synthesis of arginine-containing peptides and study on their effects upon thrombin
|
| Kibirev V. K., Poyarkova S. A., Gershkovich A. A. |
| |
|
Synthetic inhibitors of coagulation factor Xa suppress thrombin generation without affection on initial thrombin forming time
|
| Tarumi T., Ieko M., Takeda M., Naito S., Arai J., Nakabayashi T., Notoya A., Koike T. |
| |
|
Synthetic tripeptides with specific inhibitory action against Gp-Ib glycoprotein
|
| Sarigiannis I., Stauropoulos G. P., Liakopoulou-Kyriakidis M., Girtovitis F., Makris P. E. |
| |
|
Systemic enzymatic activity in blood?
|
| Butenas S., Orfeo T., Gissel M. T., Brummel K. E., Mann K. G. |
| |
